Serotype distribution and antimicrobial susceptibility of invasive Streptococcus pneumoniae isolates among adult and elderly population before and after introduction of pneumococcal conjugate vaccine in Casablanca, Morocco

Nzoyikorera, Néhémie; Diawara, Idrissa; Katfy, Mostafa; Katfy, Khalid; Maaloum, Fakhreddine; Nyandwi, Joseph; Belabbes, Houria; Elmdaghri, Naima; Zerouali, Khalid

doi:10.1186/s12879-023-07981-y

Table 1 Sample origin and IPD incidence according to age groups in the pre-and post-vaccination periods

From: Serotype distribution and antimicrobial susceptibility of invasive Streptococcus pneumoniae isolates among adult and elderly population before and after introduction of pneumococcal conjugate vaccine in Casablanca, Morocco

	Pre-vaccine period 2007–2010 no. of cases/100,000 populations^a	Post-implementation no. of cases/100.000 populations^b		Baseline (2007–2010) vs early post-vaccine period (2011–2014)			Baseline (2007–2010) vs mature post-vaccine period (2015–2019)
		Early post-vaccine period 2011–2014	Mature post-vaccine period 2015–2019	Absolute risk reduction cases/100,000 populations (95% CI)	Relative Risk Reduction % (95% CI)	p-value	Absolute risk reduction cases/100,000 populations (95% CI)	Relative risk reduction % (95% CI)	p-value
15–59 years
CSF	0.18	0.09	0.26	− 0.09 (− 0.20 to + 0.02)	− 47.53 (− 110.37 to + 9.88)	0.09	− 0.09 (− 0.20 to + 0.02)	0.73 (0.45 to 1.20)	0.19
Blood	0.35	0.37	0.16	+ 0.02 (− 0.15 to + 0.19)	+ 5.23 (− 42.98 to + 52.99)	0.82	+ 0.02 (− 0.15 to + 0.19)	0.86 (0.44 to 1.71)	0.65
Pleural fluid	0.07	0.04	0.03	− 0.03 (− 0.11 to 0.04)	− 46.03 (− 157.46 to + 53.22)	0.48	− 0.03 (− 0.11 to 0.04)	0.48 (0.12 to 1.77)	0.21
^cOthers	0.11	0.04	0.02	− 0.07 (− 0.16 to 0.00)	− 65.65 (− 147.48 to + 4.07)	0.09	− 0.07 (− 0.16 to 0.00)	0.18 (0.03 to 0.70)	0.0037
Total	0.71	0.54	0.47	− 0.17 (− 0.39 to + 0.04)	− 24.18 (− 55.51 to + 6.33)	0.02	− 0.17 (− 0.39 to + 0.04)	0.66 (0.46 to 0.93)	0.0137
≥ 60 years
CSF	0.77	0.56	0.23	− 0.20 (− 0.95 to + 0.50)	− 26.55 (− 124.25 to + 64.88)	0.53	− 0.20 (− 0.95 to + 0.50)	0.68 (0.12 to 3.65)	0.58
Blood	0.34	1.12	0.17	+ 0.78 (+ 0.08 to + 1.58)	+ 230.55 (+ 24.26 to + 463.05)	0.04	+ 0.78 (+ 0.08 to + 1.58)	0.22 (0.03 to 0.90)	0.0149
Pleural fluid	0.09	0.24	0.23	+ 0.16 (− 0.27 to + 0.63)	+ 183.32 (− 319.24 to + 739.21)	0.62	+ 0.16 (− 0.27 to + 0.63)	2.72 (0.26 to 134.03)	0.35
Other	0.09	0.16	0.06	+ 0.08 (− 0.34 to + 0.51)	+ 88.88 (− 397.33 to + 595.49)	1	+ 0.08 (− 0.34 to + 0.51)	0.68 (0.008 to 53.41)	0.78
Total	1.28	2.09	0.69	+ 0.81 (− 0.25 to + 1.91)	+ 63.70 (− 19.53 to 149.45)	0.12	+ 0.81 (− 0.25 to + 1.91)	0.54 (0.23 to 1.24)	0.11

Incidences were calculated as incidence = Number of IPD cases × 100,000/population during the years of surveillance
^aThe pre-period was from January 2007 to October 2010
^bThe post-period was from January 2011 to December 2019 and devised in the early post-vaccine period (2011–2014) and the mature post-period (2015–2019)
^cOther sterile sites (articular fluid, pus/tissues)

Back to article page

ISSN: 1471-2334

Contact us

Submission enquiries: bmcinfectiousdiseases@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Infectious Diseases

Contact us